Thi Thom Mac
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thi Thom Mac has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Teddy Fauquier
Aix-Marseille University, INSERM, UMR1251, Marseille Medical Genetics, Institut MarMaRa
5 shared publications - Thierry Brue
Aix-Marseille University, INSERM, UMR1251, Marseille Medical Genetics, Institut MarMaRa
5 shared publications - Anne Barlier
Aix Marseille Univ, APHM, INSERM, MMG, MarMaRa institute, La Timone University Hospital, Laboratory of Molecular Biology GEnOPé, BIOGENOPOLE, Marseille, France
3 shared publications - Frederic Castinetti
Aix Marseille Université INSERM, MMG, MarMaRa Institute, UMR 1251, APHM, La Conception University Hospital, Department of Endocrinology Marseille France
3 shared publications - Heather Corbett Etchevers
Aix Marseille University INSERM, Marseille Medical Genetics Marseille France
3 shared publications - Nicolas Jullien
Aix Marseille Univ, CNRS, UMR7051, Institut de NeuroPhysiopathologie
3 shared publications
Latest Publications
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Étude des déficits corticotropes congénitaux grâce à un modèle de cellules souches pluripotentes induites humaines
Le déficit corticotrope congénital est une maladie rare, définie par le déficit de la sécrétion d’ACTH (pour adrenocorticotrophic hormone) et de cortisol, pouvant être à l’origine de 25% de décès néonataux. Notre équipe fait partie du réseau international GENHYPOPIT (hypopituitarisme humain), qui a pour l’objectif de dépister les étiologies génétiques du déficit hypophysaire. Nous avons identifié des mutations des gènes codant pour des facteurs de transcription hypophysaires, qui sont impliqués dans le développement hypophysaire, chez 7% des patients. Le déficit corticotrope isolé est principalement lié à des mutations du facteur de transcription TPIT (TBX19) : notre équipe a ainsi rapporté que 65% des déficits corticotropes néonataux isolés sont liés à des variants pathogènes de TPIT (TBX19). TBX19 joue un rôle essentiel pour la différenciation terminale des cellules corticotropes. De plus, nous avons identifié pour la première fois de nouvelles mutations de NFKB2 dans le cadre du syndrome DAVID, une association du déficit corticotrope et du déficit immunitaire commun variable. Le mécanisme physiopathologique sous-jacent du déficit corticotrope reste inconnu à ce jour. Il n’est pas déterminé si les mutations de NFKB2 sont à l’origine d’un déficit corticotrope par un mécanisme développemental ou auto-immun. En effet, le modèle de souris Lym1, portant la mutation de NFKB2, présente des fonctions hypophysaires normales. Dans ce contexte, mes travaux de doctorat ont eu pour objectif principal de créer un modèle humain d'étude du déficit corticotrope congénital établi à partir de cellules souches induites pluripotentes différenciées en cellules hypophysaires. Pour atteindre nos objectifs, je me suis appuyée sur des stratégies de modélisations cellulaires basées sur les cellules souches pluripotentes induites humaines (hiPSC). J’ai combiné des approches d’édition génomique des hiPSC par CRISPR/Cas9 avec la différenciation des hiPSC en organoïdes hypophysaires grâce à une technique de culture en trois dimensions, ciblant d’abord le gène TBX19 pour valider le modèle, puis le gène NFKB2 pour étudier l’impact de NFKB2 sur le développement de cellules corticotropes humaines.La preuve de concept a été validée avec la mutation du TBX19K146R/K146R. Nous avons pu observer un déficit corticotrope dans les organoïdes différenciés à partir des hiPSC porteurs de cette mutation par rapport aux cellules témoins. Ce modèle a été ensuite utilisé pour étudier la mutation NFKB2D865G/D865G. Nos résultats ont révélé une altération du développement des cellules corticotropes dans les organoïdes différenciés à partir des hiPSC porteurs de la mutation de NFKB2. En conclusion, mes travaux ont mis en évidence l'intérêt et la puissance d’un nouveau modèle in vitro pour l'étude du déficit corticotrope congénital grâce auquel nous avons pu ainsi montrer pour la première fois le rôle de NFKB2 dans le développement hypophysaire
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Étude des déficits corticotropes congénitaux grâce à un modèle de cellules souches pluripotentes induites humaines
Le déficit corticotrope congénital est une maladie rare, définie par le déficit de la sécrétion d’ACTH (pour adrenocorticotrophic hormone) et de cortisol, pouvant être à l’origine de 25% de décès néonataux. Notre équipe fait partie du réseau international GENHYPOPIT (hypopituitarisme humain), qui a pour l’objectif de dépister les étiologies génétiques du déficit hypophysaire. Nous avons identifié des mutations des gènes codant pour des facteurs de transcription hypophysaires, qui sont impliqués dans le développement hypophysaire, chez 7% des patients. Le déficit corticotrope isolé est principalement lié à des mutations du facteur de transcription TPIT (TBX19) : notre équipe a ainsi rapporté que 65% des déficits corticotropes néonataux isolés sont liés à des variants pathogènes de TPIT (TBX19). TBX19 joue un rôle essentiel pour la différenciation terminale des cellules corticotropes. De plus, nous avons identifié pour la première fois de nouvelles mutations de NFKB2 dans le cadre du syndrome DAVID, une association du déficit corticotrope et du déficit immunitaire commun variable. Le mécanisme physiopathologique sous-jacent du déficit corticotrope reste inconnu à ce jour. Il n’est pas déterminé si les mutations de NFKB2 sont à l’origine d’un déficit corticotrope par un mécanisme développemental ou auto-immun. En effet, le modèle de souris Lym1, portant la mutation de NFKB2, présente des fonctions hypophysaires normales. Dans ce contexte, mes travaux de doctorat ont eu pour objectif principal de créer un modèle humain d'étude du déficit corticotrope congénital établi à partir de cellules souches induites pluripotentes différenciées en cellules hypophysaires. Pour atteindre nos objectifs, je me suis appuyée sur des stratégies de modélisations cellulaires basées sur les cellules souches pluripotentes induites humaines (hiPSC). J’ai combiné des approches d’édition génomique des hiPSC par CRISPR/Cas9 avec la différenciation des hiPSC en organoïdes hypophysaires grâce à une technique de culture en trois dimensions, ciblant d’abord le gène TBX19 pour valider le modèle, puis le gène NFKB2 pour étudier l’impact de NFKB2 sur le développement de cellules corticotropes humaines.La preuve de concept a été validée avec la mutation du TBX19K146R/K146R. Nous avons pu observer un déficit corticotrope dans les organoïdes différenciés à partir des hiPSC porteurs de cette mutation par rapport aux cellules témoins. Ce modèle a été ensuite utilisé pour étudier la mutation NFKB2D865G/D865G. Nos résultats ont révélé une altération du développement des cellules corticotropes dans les organoïdes différenciés à partir des hiPSC porteurs de la mutation de NFKB2. En conclusion, mes travaux ont mis en évidence l'intérêt et la puissance d’un nouveau modèle in vitro pour l'étude du déficit corticotrope congénital grâce auquel nous avons pu ainsi montrer pour la première fois le rôle de NFKB2 dans le développement hypophysaire
- Open Access
- 15 July 2025
- Published by Elsevier in La Presse Médicale
- Vol. 54 (4) , 104299
Pituitary organoids as models for congenital pituitary deficiencies
- 15 July 2025
- Published by Elsevier in La Presse Médicale
- Vol. 54 (4) , 104299
Open AccessPituitary organoids as models for congenital pituitary deficiencies
- Open Access
- 28 November 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Modeling corticotroph deficiency with pituitary organoids supports the functional role of NFKB2 in human pituitary differentiation
Deficient Anterior pituitary with common Variable Immune Deficiency (DAVID) syndrome results from NFKB2 heterozygous mutations, causing adrenocorticotropic hormone deficiency (ACTHD) and primary hypogammaglobulinemia. While NFKB signaling plays a crucial role in the immune system, its connection to endocrine symptoms is unclear. We established a human disease model to investigate the role of NFKB2 in pituitary development by creating pituitary organoids from CRISPR/Cas9-edited human induced pluripotent stem cells (hiPSCs). Introducing homozygous TBX19K146R/K146R missense pathogenic variant in hiPSC, an allele found in congenital isolated ACTHD, led to a strong reduction of corticotrophs number in pituitary organoids. Then, we characterized the development of organoids harboring NFKB2D865G/D865G mutations found in DAVID patients. NFKB2D865G/D865G mutation acted at different levels of development with mutant organoids displaying changes in the expression of genes involved on pituitary progenitor generation (HESX1, PITX1, LHX3), hypothalamic secreted factors (BMP4, FGF8, FGF10), epithelial-to-mesenchymal transition, lineage precursors development (TBX19, POU1F1) and corticotrophs terminal differentiation (PCSK1, POMC), and showed drastic reduction in the number of corticotrophs. Our results provide strong evidence for the direct role of NFKB2 mutations in the endocrine phenotype observed in patients leading to a new classification of a NFKB2 variant of previously unknown clinical significance as pathogenic in pituitary development.
- 28 November 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessModeling corticotroph deficiency with pituitary organoids supports the functional role of NFKB2 in human pituitary differentiation
Deficient Anterior pituitary with common Variable Immune Deficiency (DAVID) syndrome results from NFKB2 heterozygous mutations, causing adrenocorticotropic hormone deficiency (ACTHD) and primary hypogammaglobulinemia. While NFKB signaling plays a crucial role in the immune system, its connection to endocrine symptoms is unclear. We established a human disease model to investigate the role of NFKB2 in pituitary development by creating pituitary organoids from CRISPR/Cas9-edited human induced pluripotent stem cells (hiPSCs). Introducing homozygous TBX19K146R/K146R missense pathogenic variant in hiPSC, an allele found in congenital isolated ACTHD, led to a strong reduction of corticotrophs number in pituitary organoids. Then, we characterized the development of organoids harboring NFKB2D865G/D865G mutations found in DAVID patients. NFKB2D865G/D865G mutation acted at different levels of development with mutant organoids displaying changes in the expression of genes involved on pituitary progenitor generation (HESX1, PITX1, LHX3), hypothalamic secreted factors (BMP4, FGF8, FGF10), epithelial-to-mesenchymal transition, lineage precursors development (TBX19, POU1F1) and corticotrophs terminal differentiation (PCSK1, POMC), and showed drastic reduction in the number of corticotrophs. Our results provide strong evidence for the direct role of NFKB2 mutations in the endocrine phenotype observed in patients leading to a new classification of a NFKB2 variant of previously unknown clinical significance as pathogenic in pituitary development.
- Open Access
- 25 October 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 12
Modeling corticotroph deficiency with pituitary organoids supports the functional role of NFKB2 in human pituitary differentiation
Background Deficient Anterior pituitary with common Variable Immune Deficiency (DAVID) syndrome, combining adrenocorticotropic hormone deficiency (ACTHD) and primary hypogammaglobulinemia, is caused by NFKB2 heterozygous mutations. Nuclear factor kappa B (NFKB) signaling is a key regulator of the immune system; however, the underlying mechanism of its association with endocrine symptoms remains unknown. The role of NFKB2 in the development of the human pituitary was called into question by Nfkb2-deficient Lym1 mice, which have normal pituitary functions. Purpose The aim of this study was to create a human disease model to define the role of NFKB2 in human pituitary development. Methods We established pituitary organoids in three-dimensional (3D) culture after directed differentiation from CRISPR/Cas9-edited human induced pluripotent stem cells (hiPSC). First, we conducted a proof-of-concept study, introducing a homozygous TBX19K146R/K146R missense pathogenic variant in hiPSC, an allele found in patients with congenital isolated ACTHD. We then used the same method to produce NFKB2D865G/D865G mutant organoids, harboring the pathogenic missense variant previously identified in DAVID patients. This mutation causes a failure of NFKB2 p100 phosphorylation that blocks processing to form active NFKB2 p52. We further characterized pituitary organoid development with bulk RNA sequencing and validated findings with quantitative RT-PCR and by immunofluorescence in section and whole organoids. Results Analysis of wild-type (WT) organoids demonstrated that this in vitro model recapitulates corticotroph cell differentiation. TBX19K146R/K146R organoids conserved early expression of HESX1, but had significantly decreased PITX1, TBX19, LHX3, and POMC transcription. NFKB2D865G/D865G organoids also had dramatically reduced corticotrophs. Furthermore, NFKB2D865G/D865G significantly perturbs the expression of 67 genes known to contribute to pituitary development, among which 39 transcription factors. Differential expression was found for several growth factor genes or genes associated with the epithelial-to-mesenchymal transition and terminal endocrine differentiation. Conclusion We used a combination of CRISPR/Cas9 editing and refinement of a 3D organoid culture protocol to model human ACTHD due to TBX19 or NFKB2 mutations. The NFKB2 variant studied induced a significant decrease in corticotroph differentiation, confirming the causative role of NFKB2 in isolated or syndromic ACTHD and demonstrating for the first time a direct functional role of NFKB2 in human pituitary development.
- 25 October 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 12
Open AccessModeling corticotroph deficiency with pituitary organoids supports the functional role of NFKB2 in human pituitary differentiation
Background Deficient Anterior pituitary with common Variable Immune Deficiency (DAVID) syndrome, combining adrenocorticotropic hormone deficiency (ACTHD) and primary hypogammaglobulinemia, is caused by NFKB2 heterozygous mutations. Nuclear factor kappa B (NFKB) signaling is a key regulator of the immune system; however, the underlying mechanism of its association with endocrine symptoms remains unknown. The role of NFKB2 in the development of the human pituitary was called into question by Nfkb2-deficient Lym1 mice, which have normal pituitary functions. Purpose The aim of this study was to create a human disease model to define the role of NFKB2 in human pituitary development. Methods We established pituitary organoids in three-dimensional (3D) culture after directed differentiation from CRISPR/Cas9-edited human induced pluripotent stem cells (hiPSC). First, we conducted a proof-of-concept study, introducing a homozygous TBX19K146R/K146R missense pathogenic variant in hiPSC, an allele found in patients with congenital isolated ACTHD. We then used the same method to produce NFKB2D865G/D865G mutant organoids, harboring the pathogenic missense variant previously identified in DAVID patients. This mutation causes a failure of NFKB2 p100 phosphorylation that blocks processing to form active NFKB2 p52. We further characterized pituitary organoid development with bulk RNA sequencing and validated findings with quantitative RT-PCR and by immunofluorescence in section and whole organoids. Results Analysis of wild-type (WT) organoids demonstrated that this in vitro model recapitulates corticotroph cell differentiation. TBX19K146R/K146R organoids conserved early expression of HESX1, but had significantly decreased PITX1, TBX19, LHX3, and POMC transcription. NFKB2D865G/D865G organoids also had dramatically reduced corticotrophs. Furthermore, NFKB2D865G/D865G significantly perturbs the expression of 67 genes known to contribute to pituitary development, among which 39 transcription factors. Differential expression was found for several growth factor genes or genes associated with the epithelial-to-mesenchymal transition and terminal endocrine differentiation. Conclusion We used a combination of CRISPR/Cas9 editing and refinement of a 3D organoid culture protocol to model human ACTHD due to TBX19 or NFKB2 mutations. The NFKB2 variant studied induced a significant decrease in corticotroph differentiation, confirming the causative role of NFKB2 in isolated or syndromic ACTHD and demonstrating for the first time a direct functional role of NFKB2 in human pituitary development.
- Open Access
Modeling corticotroph deficiency with pituitary organoids supports the functional role of NFKB2 in human pituitary differentiation
Background: Deficient Anterior pituitary with common Variable Immune Deficiency (DAVID) syndrome, combining adrenocorticotropic hormone deficiency (ACTHD) and primary hypogammaglobulinemia, is caused by NFKB2 heterozygous mutations. Nuclear factor kappa B (NFKB) signaling is a key regulator of the immune system; however, the underlying mechanism of its association with endocrine symptoms remains unknown. The role of NFKB2 in the development of the human pituitary was called into question by Nfkb2 -deficient Lym1 mice, which have normal pituitary functions. Purpose: The aim of this study was to create a human disease model to define the role of NFKB2 in human pituitary development. Methods: We established pituitary organoids in three-dimensional (3D) culture after directed differentiation from CRISPR/Cas9-edited human induced pluripotent stem cells (hiPSC). First, we conducted a proof-of-concept study, introducing a homozygous TBX19 K146R/K146R missense pathogenic variant in hiPSC, an allele found in patients with congenital isolated ACTHD. We then used the same method to produce NFKB2 D865G/D865G mutant organoids, harboring the pathogenic missense variant previously identified in DAVID patients. This mutation causes a failure of NFKB2 p100 phosphorylation that blocks processing to form active NFKB2 p52. We further characterized pituitary organoid development with bulk RNA sequencing and validated findings with quantitative RT-PCR and by immunofluorescence in section and whole organoids. Results: Analysis of wild-type (WT) organoids demonstrated that this in vitro model recapitulates corticotroph cell differentiation. TBX19 K146R/K146R organoids conserved early expression of HESX1 , but had significantly decreased PITX1 , TBX19 , LHX3, and POMC transcription . NFKB2 D865G/D865G organoids also had dramatically reduced corticotrophs. Furthermore, NFKB2 D865G/D865G significantly perturbs the expression of 67 genes known to contribute to pituitary development, among which 39 transcription factors. Differential expression was found for several growth factor genes or genes associated with the epithelial-to-mesenchymal transition and terminal endocrine differentiation. Conclusion: We used a combination of CRISPR/Cas9 editing and refinement of a 3D organoid culture protocol to model human ACTHD due to TBX19 or NFKB2 mutations. The NFKB2 variant studied induced a significant decrease in corticotroph differentiation, confirming the causative role of NFKB2 in isolated or syndromic ACTHD and demonstrating for the first time a direct functional role of NFKB2 in human pituitary development.
Open AccessModeling corticotroph deficiency with pituitary organoids supports the functional role of NFKB2 in human pituitary differentiation
Background: Deficient Anterior pituitary with common Variable Immune Deficiency (DAVID) syndrome, combining adrenocorticotropic hormone deficiency (ACTHD) and primary hypogammaglobulinemia, is caused by NFKB2 heterozygous mutations. Nuclear factor kappa B (NFKB) signaling is a key regulator of the immune system; however, the underlying mechanism of its association with endocrine symptoms remains unknown. The role of NFKB2 in the development of the human pituitary was called into question by Nfkb2 -deficient Lym1 mice, which have normal pituitary functions. Purpose: The aim of this study was to create a human disease model to define the role of NFKB2 in human pituitary development. Methods: We established pituitary organoids in three-dimensional (3D) culture after directed differentiation from CRISPR/Cas9-edited human induced pluripotent stem cells (hiPSC). First, we conducted a proof-of-concept study, introducing a homozygous TBX19 K146R/K146R missense pathogenic variant in hiPSC, an allele found in patients with congenital isolated ACTHD. We then used the same method to produce NFKB2 D865G/D865G mutant organoids, harboring the pathogenic missense variant previously identified in DAVID patients. This mutation causes a failure of NFKB2 p100 phosphorylation that blocks processing to form active NFKB2 p52. We further characterized pituitary organoid development with bulk RNA sequencing and validated findings with quantitative RT-PCR and by immunofluorescence in section and whole organoids. Results: Analysis of wild-type (WT) organoids demonstrated that this in vitro model recapitulates corticotroph cell differentiation. TBX19 K146R/K146R organoids conserved early expression of HESX1 , but had significantly decreased PITX1 , TBX19 , LHX3, and POMC transcription . NFKB2 D865G/D865G organoids also had dramatically reduced corticotrophs. Furthermore, NFKB2 D865G/D865G significantly perturbs the expression of 67 genes known to contribute to pituitary development, among which 39 transcription factors. Differential expression was found for several growth factor genes or genes associated with the epithelial-to-mesenchymal transition and terminal endocrine differentiation. Conclusion: We used a combination of CRISPR/Cas9 editing and refinement of a 3D organoid culture protocol to model human ACTHD due to TBX19 or NFKB2 mutations. The NFKB2 variant studied induced a significant decrease in corticotroph differentiation, confirming the causative role of NFKB2 in isolated or syndromic ACTHD and demonstrating for the first time a direct functional role of NFKB2 in human pituitary development.
- Open Access
- 15 June 2023
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 35 (6) , e13287
Deficient anterior pituitary with common variable immune deficiency (DAVID syndrome): a new case and literature reports
Deficient anterior pituitary with common variable immune deficiency (DAVID) syndrome is a rare condition characterized by adrenocorticotropic hormone (ACTH) deficiency and primary hypogammaglobulinemia. It is due to heterozygous mutations of the nuclear factor kappa‐B subunit 2 (NFKB2) gene. Only a few isolated cases have been reported since its first description by our team. Through the international multicenter GENHYPOPIT network, we identified a new case of DAVID syndrome. We then conducted an extensive review of the DAVID syndrome cases published from 2012 to 2022. A 7‐year‐old boy was diagnosed with symptomatic hypoglycemia revealing ACTH deficiency. Laboratory tests showed asymptomatic hypogammaglobulinemia. He harbored a heterozygous point mutation in NFKB2 gene (c.2600C > T, p.Ala867Val). His management included hydrocortisone replacement treatment, and he also received subcutaneous immunoglobulins during the Covid‐19 pandemic. We analyzed 28 cases of DAVID syndrome with ACTH deficiency. ACTH deficiency was the only hormone deficiency in 79% of patients, but some patients harbored growth hormone (GH) and thyroid stimulating hormone (TSH) deficiencies. The first presenting symptoms were sinus/pulmonary infections (82%, mean age of 3 years) and alopecia (mean age of 4.7 years). ACTH deficiency was the third presenting condition (mean age at diagnosis of 8.6 years). All patients had hypogammaglobulinemia (decreased IgA and IgM levels), and 57% of patients had at least one autoimmune manifestation. Heterozygous mutations at the 3′end of the NFKB2 gene, coding for the C‐terminal domain of the protein, were identified in all cases. Better knowledge of DAVID syndrome will help clinicians make an early diagnosis to avoid life‐threatening complications.
- 15 June 2023
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 35 (6) , e13287
Open AccessDeficient anterior pituitary with common variable immune deficiency (DAVID syndrome): a new case and literature reports
Deficient anterior pituitary with common variable immune deficiency (DAVID) syndrome is a rare condition characterized by adrenocorticotropic hormone (ACTH) deficiency and primary hypogammaglobulinemia. It is due to heterozygous mutations of the nuclear factor kappa‐B subunit 2 (NFKB2) gene. Only a few isolated cases have been reported since its first description by our team. Through the international multicenter GENHYPOPIT network, we identified a new case of DAVID syndrome. We then conducted an extensive review of the DAVID syndrome cases published from 2012 to 2022. A 7‐year‐old boy was diagnosed with symptomatic hypoglycemia revealing ACTH deficiency. Laboratory tests showed asymptomatic hypogammaglobulinemia. He harbored a heterozygous point mutation in NFKB2 gene (c.2600C > T, p.Ala867Val). His management included hydrocortisone replacement treatment, and he also received subcutaneous immunoglobulins during the Covid‐19 pandemic. We analyzed 28 cases of DAVID syndrome with ACTH deficiency. ACTH deficiency was the only hormone deficiency in 79% of patients, but some patients harbored growth hormone (GH) and thyroid stimulating hormone (TSH) deficiencies. The first presenting symptoms were sinus/pulmonary infections (82%, mean age of 3 years) and alopecia (mean age of 4.7 years). ACTH deficiency was the third presenting condition (mean age at diagnosis of 8.6 years). All patients had hypogammaglobulinemia (decreased IgA and IgM levels), and 57% of patients had at least one autoimmune manifestation. Heterozygous mutations at the 3′end of the NFKB2 gene, coding for the C‐terminal domain of the protein, were identified in all cases. Better knowledge of DAVID syndrome will help clinicians make an early diagnosis to avoid life‐threatening complications.